Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 5/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 18/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.51 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.49 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4057364 | 0.89 | MTOR (0.72) | MTORPIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL4051833 | 0.87 | PIK3CA (0.57) | MTORPIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL4056512 | 0.85 | PIK3CA (0.64) | MTORPIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL4228751 | 0.85 | MTOR (0.63) | MTORPIK3CAPIK3CDPIK3CG | |
| SCHEMBL4057856 | 0.83 | MTOR (0.64) | MTORPIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL4053032 | 0.81 | MTOR (0.65) | MTORPIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL4053012 | 0.80 | MTOR (0.57) | MTORPIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL4053948 | 0.80 | MTOR (0.84) | MTORPIK3CA | |
| SCHEMBL4058302 | 0.80 | MTOR (0.84) | MTORPIK3CA | |
| SCHEMBL4056388 | 0.80 | MTOR (0.60) | MTORPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227575-A1 | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | WYETH (US) | 2009-09-10 | — | — | US | claimed |
| WO-2009111547-A1 | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | WYETH (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227575-A1 | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227575-A1 | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | MTOR, RICTOR, RPS6KA3 | MTOR 1/4885PIK3CA 19/4885PIK3CB 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.